Payment overview · 2025
General Payments
$170.20
4 reported records · 4 companies
Healthcare provider profile · identity verified
Abdul Ghani, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · ZEPHYRHILLS, FL · NPI 1699711341
Verified facts
What the public records show
CMS Open Payments records show Abdul Ghani, MD received $170.20 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.15 | 51.8% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $39.09 | 23.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.06 | 14.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.90 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.20 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.15 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $39.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 72 |
| Simvastatin | Simvastatin | 329 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 72 |
| Losartan Potassium | Losartan Potassium | 192 | 59 |
| Lisinopril | Lisinopril | 190 | 56 |
| Omeprazole | Omeprazole | 129 | 38 |
| Ozempic | Semaglutide | 126 | 22 |
| Gabapentin | Gabapentin | 125 | 27 |
| Carvedilol | Carvedilol | 118 | 34 |
| Tramadol Hcl | Tramadol Hcl | 115 | 22 |
| Alprazolam | Alprazolam | 103 | 14 |
| Furosemide | Furosemide | 102 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 24 |
| Azithromycin | Azithromycin | 93 | 56 |
| Fenofibrate | Fenofibrate | 87 | 26 |
| Metformin Hcl | Metformin Hcl | 86 | 28 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 81 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 77 | 18 |
| Potassium Chloride | Potassium Chloride | 75 | 18 |
| Famotidine | Famotidine | 73 | 22 |
| Montelukast Sodium | Montelukast Sodium | 73 | 19 |
| Jardiance | Empagliflozin | 72 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 24 |
| Trulicity | Dulaglutide | 64 | 14 |
| Prednisone | Prednisone | 63 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 15 |
| Eliquis | Apixaban | 57 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Sertraline Hcl | Sertraline Hcl | 56 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 22 |
| Trazodone Hcl | Trazodone Hcl | 55 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 16 |
| Labetalol Hcl | Labetalol Hcl | 49 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Diazepam | Diazepam | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | 11 |
| Meloxicam | Meloxicam | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 26 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 13 |
| Mometasone Furoate | Mometasone Furoate | 36 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 18 |
| Kerendia | Finerenone | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 11 |
| Atenolol | Atenolol | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Hyzaar | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.20 · 4 records | Novo Nordisk Inc | Kerendia, MOUNJARO, Ozempic, REZDIFFRA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error